I 118th CONGRESS 2d Session H. R. 8659 IN THE HOUSE OF REPRESENTATIVES June 7, 2024 Mrs. Hinson (for herself, Mrs. Miller-Meeks , Ms. Malliotakis , and Mr. Ciscomani ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committees on Ways and Means , Natural Resources , and Armed Services , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To allow women greater access to safe and effective oral contraceptive drugs intended for routine use, and to direct the Comptroller General of the United States to conduct a study on Federal funding of contraceptive methods.

1. Short title This Act may be cited as the Allowing Greater Access to Safe and Effective Contraception Act . 2. Supplemental applications for over-the-counter contraceptive drugs (a) Priority review of application The Secretary of Health and Human Services (referred to in this section as the Secretary ) shall give priority review to any supplemental application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(b) ) if— (1) the supplemental application is with respect to an oral contraceptive drug intended for routine use; (2) the supplemental application is not with respect to— (A) any emergency contraceptive drug; or (B) any drug that is also approved for induced abortion; and (3) if the supplemental application is approved, with respect to individuals aged 18 and older, such drug would not be subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 353(b)(1) ). (b) Fee waiver The Secretary shall waive the fee under section 736(a)(1) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379h(a)(1) ) with respect to a supplemental application that receives priority review under subsection (a). (c) Over-the-Counter availability Notwithstanding any other provision of law, with respect to individuals under age 18, a contraceptive drug that is eligible for priority review under subsection (a) shall be subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 353(b)(1) ), including after approval of the supplemental application as described in subsection (a)(3). (d) Applicability This section applies with respect to a supplemental application described in subsection (a) that— (1) is submitted before the date of enactment of this Act and remains pending as of such date of enactment; or (2) is submitted after such date of enactment. 3. GAO study and report on Federal funding of contraceptive methods Not later than one year after the date of enactment of this Act, the Comptroller General of the United States shall conduct a study and submit a report to Congress regarding the amount of Federal funds made available for the purposes of contraception reimbursement, inventory stocking, provider training, or patient education during the 15-year period immediately preceding such date of enactment, including such funding made available through— (1) the Medicare program under title XVIII of the Social Security Act ( 42 U.S.C. 1395 et seq. ); (2) the Medicaid program under title XIX of the Social Security Act ( 42 U.S.C. 1396 et seq. ); (3) the Indian Health Service; (4) the American Health Benefit Exchanges established under section 1311 or 1321 of the Patient Protection and Affordable Care Act ( 42 U.S.C. 18031 ; 18041); (5) Federally-qualified health centers (as defined in section 1905(l)(2)(B) of the Social Security Act ( 42 U.S.C. 1396d(l)(2)(B) )); (6) title X of the Public Health Service Act ( 42 U.S.C. 300 et seq. ); (7) temporary assistance for needy families under part A of title IV of the Social Security Act ( 42 U.S.C. 601 et seq. ); or (8) the TRICARE program (as defined in section 1072 of title 10, United States Code).